INTRODUCTION {#S1}
============

Alzheimer's disease (AD) is a progressive and incurable neurodegenerative disorder that is estimated to affect 13 million people in the United States by 2050 ([@R3]). At autopsy, AD is characterized by extracellular neuritic plaques and intraneuronal neurofibrillary tangles, predominantly composed of misfolded and aggregated β-amyloid (Aβ) peptide and the microtubule-associated protein tau (MAPT or Tau), respectively ([@R76]). Substantial evidence indicates that AD pathology disrupts synaptic function at an early stage, and synapse loss is strongly associated with clinical progression ([@R84]). Human genomewide association studies (GWASs) have discovered nearly 30 common variants associated with AD risk ([@R36]; [@R45]; [@R47]); however, most of these newly implicated genes remain poorly studied, especially in the nervous system. In prior work, we leveraged a human *MAPT* transgenic model in the fruit fly, *Drosophila melanogaster,* to identify AD susceptibility gene candidates that interact with Tau-mediated mechanisms ([@R78]). Among our findings, knockdown of *cindr,* the ortholog of the AD risk gene CD2-associated protein (*CD2AP*), enhanced Tau-induced neurodegeneration.

Before its identification from AD GWASs, loss-of-function mutations in *CD2AP* were identified as a rare cause of familial, autosomal dominant, focal segmental glomerulosclerosis, and progressive renal dysfunction has been recapitulated in mice hetero- or homozygous for a *Cd2ap* knockout allele ([@R41]; [@R77]). *CD2AP* encodes an adaptor protein that contains three SH3 motifs, a proline-rich region, and an actin binding domain ([@R23]). In the kidney, *CD2AP* is required to maintain structural integrity of the slit diaphragm, the specialized junctions between the foot processes of glomerular podocytes. Additional studies support a role for CD2AP in cytoskeletal anchoring of adhesion complexes ([@R37]; [@R54]) and regulation of membrane localization for cell surface receptors via endocytosis ([@R39]; [@R60]). Several other AD susceptibility loci harbor genes with links to cell adhesion (*CASS4, FERMT2,* and *PTK2B*) and endocytosis (*BIN1, PICALM,* and *RIN3*). Nevertheless, the function of *CD2AP* in the adult nervous system, or its mechanism in neurological disorders, remains largely unknown. Studies in mice have connected CD2AP to both axonal growth ([@R34]) and maintenance of blood-brain barrier integrity ([@R17]). *CD2AP* has also been implicated in amyloid precursor protein trafficking and processing in cultured neurons ([@R87]), although *Cd2ap* loss of function did not affect total Aβ levels or amyloid plaque burden in AD mouse models ([@R49]).

Besides suggesting potential interactions with Tau ([@R78]), investigations in the fruit fly have implicated *cindr* with conserved roles in nephrocytes ([@R27]), retinal development ([@R37], [@R39]), and oogenesis ([@R31]). Here, we have used *Drosophila* to elucidate the role of *cindr* in the nervous system, confirming a requirement for synaptic vesicle endocytosis and revealing requirements for ubiquitin-proteasome-mediated protein turnover and presynaptic Ca^2+^ homeostasis. Moreover, we present evidence that the role of CD2AP in synaptic proteostasis is conserved in the mammalian brain and may contribute to vulnerability for Tau-mediated neurotoxic mechanisms in AD.

RESULTS {#S2}
=======

Cindr Is Expressed in the Nervous System and Associates with Synaptic Proteins {#S3}
------------------------------------------------------------------------------

We first characterized the expression and subcellular localization of Cindr in the *Drosophila* nervous system ([Figures 1](#F1){ref-type="fig"} and [S1](#SD1){ref-type="supplementary-material"}). Consistent results were obtained using either a published anti-Cindr antibody ([@R37]) or an available allele, *cindr*^*CA06686*^ ([@R12]), referred to hereafter as *cindr*^*GFP*^, that encodes a functional, GFP-tagged protein under the control of endogenous genomic regulatory elements ([Figure 1A](#F1){ref-type="fig"}). Neither Cindr^GFP^ nor anti-Cindr antibody permit detection of all predicted, alternative protein isoforms. Nevertheless, *cindr* appears to be expressed ubiquitously, including in both the adult and the larval nervous system ([Figures 1](#F1){ref-type="fig"} and [S1](#SD1){ref-type="supplementary-material"}). In the adult brain, Cindr appears enriched within the neuropil, where it colocalizes with the presynaptic marker Bruchpilot (nc82) ([@R94]) ([Figure 1B](#F1){ref-type="fig"}). Cindr is also present at photoreceptor presynaptic terminals in the lamina ([Figure S1C](#SD1){ref-type="supplementary-material"}). Besides widespread neuronal expression, Cindr is detectable in glial cells ([Figure S1E](#SD1){ref-type="supplementary-material"}). In larval preparations, Cindr staining reveals a punctate distribution within the body wall musculature and appears enriched predominantly at the presynapse of the neuromuscular junction (NMJ) ([Figures 1C](#F1){ref-type="fig"} and [S1F](#SD1){ref-type="supplementary-material"}). Within the presynaptic bouton, Cindr is detectable both at the membrane and in a predominantly patchy, cytoplasmic distribution in which puncta are also observed ([Figures 1D](#F1){ref-type="fig"} and [S1F](#SD1){ref-type="supplementary-material"}).

To identify proteins that interact with Cindr, we performed immunoprecipitation (IP) followed by mass spectrometry (MS). Homogenates from adult fly heads were prepared from *cindr*^*GFP*^ animals, and IP was performed using a high-affinity anti-GFP antibody ([@R64]). Based on MS peptide counts, Cindr associates with actin, as expected, and several other candidate binding partners, including proteins related to synaptic transmission ([Table S1](#SD1){ref-type="supplementary-material"}). Directed coimmunoprecipitation (coIP) was performed for independent confrmation of selected interaction partners ([Figure 1E](#F1){ref-type="fig"}). For these experiments, we expressed Cindr using the pan-neuronal driver *Elav-GAL4* and a cDNA transgene encoding a Cindr:GFP fusion protein under control of the heterologous upstream activating sequence (*UAS*) (*Elav\>cindr*). We confirmed the interaction with actin and validated associations with presynaptic proteins, including the Ca^2+^ sensor Synaptotagmin ([@R51]) and the synaptic vesicle reserve pool marker Synapsin ([@R42]; [@R14]). Cindr showed partially overlapping localization *in vivo* with potential synaptic binding partners at the larval NMJ, including both Synapsin and Synaptotagmin ([Figure 1D](#F1){ref-type="fig"}). Cindr also bound the plasma membrane calcium ATPase (PMCA), a regulator of calcium homeostasis; 26S regulatory proteasomal subunit 5 (Rpt5); and the homolog of the adaptor protein 14-3-3ζ, known as Leonardo in *Drosophila,* which has been previously implicated in synaptic function ([@R11]; [@R79]). Based on its localization and interaction partners, these data suggest that Cindr may play a role at the synapse in *Drosophila.*

*cindr* Is Required for Synaptic Maturation {#S4}
-------------------------------------------

Prior studies of *cindr* in *Drosophila* have relied on knockdown experiments with RNAi strains or transgenic overexpression ([@R37]; [@R27]). We generated a null allele, *cindr*^*1*^, via Flippase (FLP)-mediated recombination between two flanking PiggyBac transposable elements harboring Flippase recognition target (FRT) sites ([@R18]; [@R73]), deleting the entire gene ([Figure 1A](#F1){ref-type="fig"}). *cindr* mRNA transcripts were undetectable in *cindr*^*1*^ homozygotes, confirming that it is a null allele ([Figure S1A](#SD1){ref-type="supplementary-material"}). In homozygosity, *cindr*^*1*^ is semi-lethal, with approximately 30% of the expected number of adults eclosing ([Figure S2B](#SD1){ref-type="supplementary-material"}), and we found similar reduced viability and survival ([Figure 2A](#F2){ref-type="fig"}) when *cindr*^*1*^ was crossed to a deficiency strain *(Df(3R)Exel6217),* which deletes most of the *cindr* locus after the 3^rd^ exon ([Figure 1A](#F1){ref-type="fig"}). In *cindr*^*1*^*/Df(3R) Exel6217* trans-heterozygotes (hereafter called *cindr*^*1/Df*^), we documented an 88% reduction in mRNA transcripts ([Figure S1A](#SD1){ref-type="supplementary-material"}), and Cindr protein was undetectable in the adult brain using anti-Cindr, which is directed against a C-terminal epitope ([Figure S1B](#SD1){ref-type="supplementary-material"}). Based on our studies, *cindr*^*1/Df*^ produces phenotypes consistent with that of the confirmed molecular null genotype *cindr*^*1*^, and in all cases loss-of-function phenotypes were fully rescued by either a 38- or a 90-kb P\[acman\] bacterial artificial chromosome ([@R92]) containing the *cindr* genomic locus ([Figure 1A](#F1){ref-type="fig"}). We cannot exclude the possibility of expression of a truncated Cindr protein in *cindr*^*1/Df*^ animals, comprising a 350 amino acid, N-terminal fragment including the SH3 domains only ([Figure S2A](#SD1){ref-type="supplementary-material"}); however, if present, our data suggest it is unlikely to be functional.

To elucidate potential requirements for *cindr* in CNS development and/or maintenance, we examined aged adults. Based on H&E staining of paraffin brain sections, we did not observe obvious morphological defects or evidence of neurodegeneration in 30-day-old *cindr*^*1/Df*^ or *cindr*^*1*^ animals ([Figures 2B](#F2){ref-type="fig"} and [S2C](#SD1){ref-type="supplementary-material"}). However, consistent with previous studies in flies ([@R37]) and mammalian cells ([@R104]), rhodamine-phalloidin staining revealed increased F-actin throughout the adult brain of *cindr*^*1/Df*^ animals ([Figure S3A](#SD1){ref-type="supplementary-material"}). Prior published work has implicated *cindr* in developmental pattering of the retina ([@R37]), but based on transmission electron microscopy (TEM), we did not detect overt evidence of ommatidial patterning defects or retinal degeneration in aged *cindr*^*1/Df*^ adults ([Figures 2B](#F2){ref-type="fig"} and [S4](#SD1){ref-type="supplementary-material"}). We also confirmed normal patterning of photoreceptor projections in the lamina ([Figures S3C](#SD1){ref-type="supplementary-material"} and [S4](#SD1){ref-type="supplementary-material"}), and electroretinograms did not reveal detectable impairment in phototransduction ([Figure S3D](#SD1){ref-type="supplementary-material"}). Nevertheless, we cannot exclude a retinal requirement for *cindr* that resolves before eclosion of homozygous adult escapers or during aging, because prior studies focused on pupal stages ([@R37], [@R38], [@R39]).

Given its enrichment at presynaptic terminals and interaction with synaptic proteins, we next explored a potential requirement for Cindr at synapses, taking advantage of the larval NMJ ([@R7]; [@R25]; [@R33]). Based on confocal microscopy, neither bouton size nor overall number of synaptic terminals was altered in *cindr*^*1/Df*^ animals ([Figures S5A](#SD1){ref-type="supplementary-material"} and [S5B](#SD1){ref-type="supplementary-material"}). We next stained for several synaptic vesicle-associated proteins, including Synaptotagmin and Synapsin, which both coIP with Cindr. While the expression and distribution of Synaptotagmin and EPS15 appeared normal ([Figures S5C](#SD1){ref-type="supplementary-material"}--[S5F](#SD1){ref-type="supplementary-material"}), we discovered a nearly 2-fold increase in Synapsin protein levels in *cindr*^*1/Df*^ animals ([Figures 2C](#F2){ref-type="fig"} and [2E](#F2){ref-type="fig"}). In addition, when costaining for pre- and postsynaptic markers, we noted an increase in the number of incompletely differentiated boutons in either *cindr*^*1/Df*^ or *cindr*^*1*^ animals ([Figures 2D](#F2){ref-type="fig"}, [2F](#F2){ref-type="fig"}, [S2D](#SD1){ref-type="supplementary-material"}, and [S3B](#SD1){ref-type="supplementary-material"}). Such NMJ terminals that show labeling with presynaptic markers, but not postsynaptic markers, have been termed ghost boutons ([@R66]) and can be observed in mutants that disrupt synaptic differentiation and/or activity-dependent synaptic remodeling ([@R4]; [@R70]; [@R91]). We validated that the *cindr* genomic construct fully rescues both the ghost bouton phenotype and the Synapsin protein elevations ([Figures 2E](#F2){ref-type="fig"} and [2F](#F2){ref-type="fig"}). We confirmed rescue of the *cindr*^*1/Df*^ ghost bouton phenotype by cell-type-specific expression of *cindr* in neurons *(Elav\>cindr)* ([Figure S5G](#SD1){ref-type="supplementary-material"}), consistent with a cell autonomous requirement.

To determine synaptic bouton ultrastructure, we performed TEM in cindr^1/Df^ larvae ([Figures 2G](#F2){ref-type="fig"}--[2I](#F2){ref-type="fig"} and [S6](#SD1){ref-type="supplementary-material"}). A substantial proportion (13%) of *cindr*^*1/Df*^ NMJ boutons lacked a sub-synaptic reticulum and active zones ([Figures 2H](#F2){ref-type="fig"} and [S6E](#SD1){ref-type="supplementary-material"}), and they likely correspond to ghost boutons detected by confocal microscopy ([Figure 2D](#F2){ref-type="fig"}). We never observed this phenotype in TEM of controls (*GR1/+; cindr*^*1/Df*^). Following *cindr* loss of function, synaptic terminals frequently were abnormally elongated, consistent with impaired differentiation and/or maintenance of synaptic morphology ([Figures S6B](#SD1){ref-type="supplementary-material"} and [S6E](#SD1){ref-type="supplementary-material"}). Overall, *cindr*^*1/Df*^ NMJ boutons exhibited a 43% reduction in mean synaptic vesicle density, along with increased numbers of aberrant, enlarged vesicles ([Figures 2I](#F2){ref-type="fig"}, [S6F](#SD1){ref-type="supplementary-material"}, and [S6G](#SD1){ref-type="supplementary-material"}), as previously reported in mutants that disrupt synaptic vesicle endocytosis ([@R7]; [@R33]; [@R44]; [@R103]). Altogether, these data suggest that *cindr* may act at the nerve terminal to influence synapse maturation, expression of the vesicle-associated protein Synapsin, and regulation of synaptic vesicle dynamics.

*cindr* Is Required for Synaptic Transmission and Plasticity {#S5}
------------------------------------------------------------

We next performed electrophysiological recordings to investigate whether *cindr* is required for normal synaptic function. We found that both amplitude and frequency of NMJ miniature excitatory junction potentials (mEJPs) in *cindr*^*1/Df*^ animals were similar to controls ([Figures S7A](#SD1){ref-type="supplementary-material"}--[S7C](#SD1){ref-type="supplementary-material"}). By contrast, in experiments performed using extracellular Ca^2+^ concentrations between 0.25 and 0.75 mM, the *cindr*^*1/Df*^ NMJ showed a reduction in evoked excitatory junction potential (EJP) amplitude ([Figures 3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}), and consistent results were seen in *cindr*^*1*^ homozygotes ([Figure S2E](#SD1){ref-type="supplementary-material"}). However, when we increased extracellular calcium to 1.5 mM, the EJP amplitude was normalized. Although we accounted for potential nonlinear summation, our experimental design relying on current clamp cannot definitively exclude subtle differences in evoked release at higher Ca^2+^. *cindr* mutants also showed defects in activity-dependent synaptic plasticity. To examine paired-pulse facilitation, we administered 2 current pulses separated by 50 ms. Facilitation was enhanced approximately 2-fold in either *cindr*^*1/Df*^ or *cindr*^*1*^ animals ([Figures 3C](#F3){ref-type="fig"}, [3D](#F3){ref-type="fig"}, and [S2F](#SD1){ref-type="supplementary-material"}). This result, in combination with the observed EJP reduction, suggests that loss of *cindr* compromises synaptic vesicle release probability. However, upon long-term (10 min), high-frequency (10 Hz) stimulation, *cindr*^*1/Df*^ animals exhibited a marked synaptic depression ([Figures 3E](#F3){ref-type="fig"} and [3F](#F3){ref-type="fig"}), which is characteristic of mutants that are unable to sustain synaptic vesicle release because of defective endocytosis ([@R7]; [@R33]; [@R44]). Although we estimated a cumulative release of \~154,000 synaptic vesicles by the *cindr*^*1/Df*^ NMJ terminal during the 10-min trial, this was significantly less than controls (\~220,000) ([Figure 3G](#F3){ref-type="fig"}). Moreover, during a follow-up period of low-frequency stimulation (0.2 Hz), *cindr* mutants showed an initial recovery but subsequently plateaued ([Figure 3F](#F3){ref-type="fig"}), suggesting that endocytic recycling persists but at a significantly diminished capacity. Overall, these neurophysiological data, along with the TEM results (described earlier) support a dual role for Cindr in both synaptic vesicle exocytosis and endocytosis at the larval NMJ.

Endocytic mutants do not typically exhibit an acute exocytic defect. The exocytic phenotype observed in *cindr* mutants might therefore arise from either reduced cytosolic Ca^2+^ or dysfunction in the protein machinery required to couple Ca^2+^ to synaptic vesicle release ([@R25]; [@R33]). To differentiate between these possibilities, we next examined the relationship between experimental extracellular Ca^2+^ concentrations (\[Ca^2+^\]) and EJP. Although the Ca^2+^ cooperativity of release (slope) was not affected, the curve was shifted to the right in *cindr*^*1/Df*^ animals ([Figure 3H](#F3){ref-type="fig"}). Thus, higher extracellular \[Ca^2+^\] is required to achieve the same evoked response, suggesting that loss of *cindr* leads to a reduced sensitivity to extracellular Ca^2+^. We next evaluated presynaptic Ca^2+^ levels using a GCaMP sensor. The selected transgenic construct *UAS-GCaMP6m-P2A-mCHERRY* ([@R1]; [@R88]) permits ratiometric normalization to an mCHERRY internal standard. In experiments performed either at resting conditions or following stimulation with 90 mM potassium chloride, *cindr*^*1/Df*^ animals exhibit reduced cytoplasmic Ca^2+^ levels across a range of conditions (extracellular \[Ca^2+^\] = 0--1.5 mM) ([Figures 4A](#F4){ref-type="fig"}, [4B](#F4){ref-type="fig"}, [S7D](#SD1){ref-type="supplementary-material"}, and [S7E](#SD1){ref-type="supplementary-material"}).

As introduced earlier, we discovered and validated the PMCA as a Cindr binding partner ([Table S1](#SD1){ref-type="supplementary-material"}; [Figure 1E](#F1){ref-type="fig"}), consistent with a potential role in calcium homeostasis. PMCA removes cytoplasmic Ca^2+^, thereby maintaining appropriate concentrations for cell signaling and neurotransmission ([@R32]). Loss of *cindr* resulted in a 2-fold increase of PMCA expression at the NMJ ([Figures 4C](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}). We therefore hypothesized that increased PMCA activity might account for the reduced basal synaptic \[Ca^2+^\] in *cindr* mutants. PMCA exchanges extracellular H^+^ for intracellular Ca^2+^ ([@R65]; [@R81]); therefore, increasing extracellular pH would be expected to antagonize its function ([@R52]). Basic conditions (pH 8.8) restored presynaptic Ca^2+^ at the *cindr*^*1/Df*^ NMJ ([Figures 4A](#F4){ref-type="fig"}, [4B](#F4){ref-type="fig"}, and [S7F](#SD1){ref-type="supplementary-material"}), and both EJP and paired-pulse responses were normalized ([Figures 4E](#F4){ref-type="fig"}, [4F](#F4){ref-type="fig"}, [S7G](#SD1){ref-type="supplementary-material"}, and [S7H](#SD1){ref-type="supplementary-material"}), consistent with a role for PMCA. Altogether, our results suggest that Cindr regulates neuronal Ca^2+^ homeostasis, potentially via PMCA, and that loss of *cindr* consequently impairs synaptic transmission and plasticity.

*cindr* Regulates Ubiquitin-Proteasome System Function {#S6}
------------------------------------------------------

Similar to our findings at larval NMJs, loss of *cindr* causes elevations of Synapsin and PMCA in the adult brain ([Figures 5A](#F5){ref-type="fig"}, [5B](#F5){ref-type="fig"}, [S2G](#SD1){ref-type="supplementary-material"}, and [S2H](#SD1){ref-type="supplementary-material"}). Because *synapsin* and *PMCA* mRNA levels appear unaffected ([Figure S8A](#SD1){ref-type="supplementary-material"}), we hypothesized that Cindr may affect protein turnover of some binding partners via the ubiquitin-proteasome system (UPS). We found that Cindr associates with the 26S proteasomal subunit Rpt5 ([Figure 1E](#F1){ref-type="fig"}), and CD2AP has been linked to proteasome function in other contexts ([@R43]; [@R86]). In addition, the UPS has previously been implicated to regulate both Synapsin levels ([@R24]; [@R48]; [@R62]) and synaptic function ([@R10]). Using a previously validated RNAi strain ([@R53]), we confirmed that knockdown of the essential proteasome subunit *RPT6A* (*Elav \> RPT6*^*RNAi*^[*)*]{.smallcaps} similarly resulted in elevated Synapsin and PMCA levels ([Figures S8B](#SD1){ref-type="supplementary-material"} and [S8C](#SD1){ref-type="supplementary-material"}). To determine whether proteasome activity is impaired in *cindr* mutants, we first employed an *in vivo* reporter line in which GFP is fused with the CL1 degron, a signal sequence for ubiquitination and proteasome targeting ([@R68]). When expressed in the adult brain using a pan-neuronal driver (*Elav\>GFP-CL1*), the resulting GFP-CL1 fusion protein was barely detected, consistent with its rapid degradation ([Figure 5C](#F5){ref-type="fig"}). By contrast, we observed a significantly increased signal of the *Elav\>GFP-CL1* reporter in *cindr*^*1/Df*^ animals ([Figures 5C](#F5){ref-type="fig"} and [5D](#F5){ref-type="fig"}), suggesting enhanced perdurance of the reporter because of impaired UPS-mediated turnover. Consistent results were also obtained using an *in vitro* proteasome activity assay in which a fluorescent peptide substrate (Suc-LLVY-AMC) is liberated following cleavage. Homogenates prepared from *cindr*^*1/Df*^ or *cindr*^*1*^ larvae (normalized for total protein levels) showed a \~30% reduction in UPS activity ([Figure 5E](#F5){ref-type="fig"}). Consistent with this, we detected a concomitant increase in polyubiquitinated proteins at the *cindr*^*1/Df*^ larval NMJ ([Figures S8D](#SD1){ref-type="supplementary-material"} and [S8E](#SD1){ref-type="supplementary-material"}) and in adult fly heads ([Figure 5F](#F5){ref-type="fig"}), suggesting broader changes in the neuronal proteome. Overall, these data are consistent with a model in which loss of *cindr* disrupts UPS function and proteostasis, leading to elevations in PMCA and Synapsin and resulting impairments in Ca^2+^ homeostasis and synaptic function.

A large body of work links the UPS and altered neuronal proteostasis to AD pathogenesis ([@R100]). Specifically, prior studies of AD transgenic mouse models and human postmortem tissue indicate that Tau-paired helical filaments can disrupt proteasome function ([@R40]; [@R61]). We previously found that RNAi-mediated knockdown of *cindr* enhances the neurotoxicity of human Tau in the fly retina ([@R78]). Using the *cindr*^*1*^ null allele, we confirmed that *cindr* loss enhances age-dependent apoptotic neurodegeneration in the adult brain following pan-neuronal expression of human Tau (Elav \> *Tau*^*R406W*^) ([Figures S9A](#SD1){ref-type="supplementary-material"} and [S9B](#SD1){ref-type="supplementary-material"}). Because *cindr* mutants impair protein turnover via the UPS, we reasoned that this could explain the observed genetic interaction with Tau toxicity. To address this, we deployed the GFP-CL1 proteasome reporter in the Tau transgenic fly. Consistent with studies in mammalian AD models, Tau triggered a marked increase in detectable GFP reporter levels from adult fly brains ([Figures S9C](#SD1){ref-type="supplementary-material"}--[S9E](#SD1){ref-type="supplementary-material"}). Thus, Tau-mediated toxicity and loss of function in *cindr* similarly converge to disrupt UPS activity in the *Drosophila* brain.

14-3-3ζ Mediates *cindr* Function at the Synapse {#S7}
------------------------------------------------

To better understand the mechanism by r which *cindr* regulates synaptic proteostasis and function, we examined another binding partner highlighted by IP-MS, the *Drosophila* ortholog of 14-3-3ζ. The *14-3-3ζ* mutants have been reported to cause reduced EJPs and increased presynaptic facilitation ([@R11]), similar to what we observe in *cindr* mutants. Moreover, 14-3-3 proteins have previously been shown to interact with and modulate UPS activity ([@R30]; [@R71]). Using a viable hypomorphic allele, *14-3-3ζ*^*2.3*^, we confirmed reduced NMJ synaptic strength ([Figures 6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}) and discovered that *14-3-3ζ*^*2.3*^ phenocopies the *cindr* ghost bouton phenotype ([Figures 6C](#F6){ref-type="fig"} and [S10A](#SD1){ref-type="supplementary-material"}). Panneuronal overexpression of *14-3-3ζ* (but not *cindr)* caused a decrease in the number of immature boutons at the NMJ ([Figures 6D](#F6){ref-type="fig"} and [S10C](#SD1){ref-type="supplementary-material"}). Moreover, *cindr* and *14-3-3ζ* showed evidence of dominant genetic interactions for both the ghost bouton and the EJP phenotypes. Specifically, in double-heterozygous allelic combinations of *cindr*^*1*^ with either *14-3-3ζ*^*2.3*^ ([Figures 6A](#F6){ref-type="fig"}--[6C](#F6){ref-type="fig"}) or a null allele, *14-3-3ζ*^*12BL*^ ([Figure S10B](#SD1){ref-type="supplementary-material"}), we discovered reduced EJP amplitudes and increased NMJ ghost boutons similar to either *cindr*^*1*^*/Df(3R)Exel3217* or *14-3-3ζ*^*2.3*^ homozygotes. This genetic interaction also suggests that 14-3-3ζ and Cindr proteins may associate in a complex and function coordinately to promote synaptic transmission, consistent with their colP ([Figure 1E](#F1){ref-type="fig"}). In addition, when *14-3-3ζ* was overexpressed in a *cindr* mutant genetic background *(Elav-Gal4/+; cindr*^*1*^*/UAS-14-3-3ζ-cDNA, Df(3R)Exel3217*), the *cindr* mutant phenotype was epistatic, resulting in increased numbers of ghost boutons ([Figure 6D](#F6){ref-type="fig"}). Consistent with these observations, we discovered that 14-3-3ζ protein levels were sharply reduced in *cindr*^*1*^ animals, even in *cindr*^*1/+*^ heterozygotes ([Figures 6E](#F6){ref-type="fig"}--[6H](#F6){ref-type="fig"}). Our results suggest that Cindr is required for proper *14-3-3ζ* protein levels and that these proteins function together at the synapse.

Lastly, we investigated whether 14-3-3ζ and *cindr* act cooperatively in regulating UPS function. Using the *in vitro* fluorometric proteasome activity assay, we first confirmed that UPS activity was similarly impaired in *14-3-3ζ*^*2.3*^ mutants ([Figure 5E](#F5){ref-type="fig"}). Next, we examined PMCA and Synapsin protein levels. As expected, based on the genetic interactions described earlier, we found that *14-3-3ζ* loss of function caused an increase in Synapsin and PMCA protein expression, whereas overexpression caused a reciprocal decrease ([Figures S10D](#SD1){ref-type="supplementary-material"} and [S10E](#SD1){ref-type="supplementary-material"}). Altogether, our findings reveal a regulatory pathway in which Cindr functions to maintain *14-3-3ζ* expression, which in turn targets Synapsin and PMCA for UPS-mediated degradation, thereby promoting synapse maturation and function.

CD2AP Has a Conserved Role in Synaptic Proteostasis {#S8}
---------------------------------------------------

Our studies uncover a role for *cindr* in synaptic proteostasis and vulnerability for Tau-mediated neurotoxicity and therefore inform how *CD2AP* might contribute to AD susceptibility. To determine whether the function of *cindr* in regulating UPS is conserved in mammals, we obtained available *Cd2ap* germline knockout mice ([@R77]). CD2AP is expressed in the mammalian brain ([@R34]), and homozygous null animals are viable with late-onset renal insufficiency. Western blots performed on brain homogenates prepared from 5-month-old *Cd2ap* null animals revealed elevations in the synaptic proteins Synapsin-1 and Synaptophysin, as well as PMCA ([Figures 7A](#F7){ref-type="fig"} and [7B](#F7){ref-type="fig"}). Reciprocally, as in *Drosophila,* we discovered that 14-3-3ζ protein is reduced. Moreover, these changes were accompanied by an approximately 20% decrease in proteasome activity ([Figure 7C](#F7){ref-type="fig"}). These data highlight a conserved role for CD2AP in regulating UPS function and synaptic proteostasis in the mammalian brain.

Finally, we leveraged available data from a large clinical-pathological human cohort study to evaluate the potential translational relevance of our findings. The Religious Orders Study and Rush Memory and Aging Project (ROSMAP) recruits older adults without known dementia for annual clinical evaluations followed by brain autopsy and comprehensive neuropathological evaluations at the time of death ([@R8]) ([Table S2](#SD1){ref-type="supplementary-material"}). Using selective reaction monitoring-MS proteomics, we quantified levels of CD2AP and homologs of Synapsin in postmortem cortical tissue samples from 838 brains and examined their relationship. Our results showed a highly significant anti-correlation between CD2AP and Synapsin-1 (p \< 0.0001, [Figure 7D](#F7){ref-type="fig"}), and other human Synapsin paralogs ([Figure S11](#SD1){ref-type="supplementary-material"}). This relationship was robust to adjustment for AD pathology, age of death, sex, and postmortem interval ([Tables S3](#SD1){ref-type="supplementary-material"} and [S4](#SD1){ref-type="supplementary-material"}). In a stratified analysis, the association between CD2AP and Synapsin levels was enhanced in the presence of AD pathology (p~interaction~ = 0.005, [Figure S11](#SD1){ref-type="supplementary-material"}). These data support a conserved role for CD2AP in synaptic proteostasis in the human brain.

DISCUSSION {#S9}
==========

*CD2AP* is an AD susceptibility gene ([@R47]), but to date, its function in the adult nervous system is poorly defined. Our cross-species experimental strategy implicates Cindr in synaptic biology and defines potential links to AD pathogenic mechanisms. First, we show that Cindr is present at the synapse and interacts with other presynaptic proteins. Second, *cindr* loss of function causes impairments in synapse maturation and synaptic vesicle recycling and release. Third, the synaptic structural and functional defects are directly linked to requirements for Cindr in UPS-mediated protein turnover and Ca^2+^ homeostasis. Lastly, we show that Cindr functions with 14-3-3ζ to regulate proteasome activity, and this role is likely conserved in mouse and human brains. Our results therefore enhance our understanding of *cindr/CD2AP* and suggest potential mechanisms for its contribution to AD susceptibility.

*cindr* Regulates Ca^2+^ Homeostasis, Neurotransmission, and Plasticity at Synapses {#S10}
-----------------------------------------------------------------------------------

Synaptic loss is strongly associated with cognitive decline in AD ([@R22]), and both Aβ and Tau have been linked to synaptic dysfunction ([@R84]). In *Drosophila,* loss of *cindr* causes a combination of endocytic and exocytic synaptic defects. Prior studies have implicated *cindr/CD2AP* in endocytosis in other contexts ([@R19]; [@R39]; [@R54]). Consistent with this, loss of *cindr* caused a reduced synaptic vesicle density at the NMJ and depression of synaptic responses during high-frequency stimulation, reminiscent of other genes implicated in endocytosis ([@R7]; [@R33]). Notable among these is *like-AP180* ([@R103]), which is homologous to another AD susceptibility gene *PICALM*. Loss of *cindr* caused reduced evoked potentials and enhanced facilitation, which both result from diminished presynaptic Ca^2+^, possibly because of increased PMCA levels. Altered Ca^2+^ handling has also been linked to AD pathogenesis ([@R26]), in which PMCA has been implicated ([@R9]; [@R57]). PMCA is a Ca^2+^ efflux pump with an established requirement for neuronal Ca^2+^ homeostasis ([@R32]). We were able to rescue *cindr* phenotypes either directly through increasing extracellular \[Ca^2+^\] or indirectly by manipulating buffer pH to suppress PMCA activity; however, we cannot exclude the possibility that other Ca^2+^ channels or transporters may participate. Overall, we confirm a role for Cindr in synaptic vesicle endocytosis and recycling and highlight an unexpected requirement for presynaptic Ca^2+^ homeostasis and resulting vesicle exocytosis and release.

Actin cytoskeletal dynamics have been implicated in synaptic vesicle recycling and plasticity, including at the *Drosophila* NMJ ([@R2]; [@R70]; [@R95]; [@R105]). Cindr is an actin binding protein, and we found that *cindr* loss of function stabilizes F-actin in the *Drosophila* nervous system, consistent with prior studies in both flies and human cells ([@R37]; [@R96]; [@R104]). Changes in actin could potentially influence many functions and phenotypes addressed in our study. Pharmacological manipulations that disrupt actin have been reported to attenuate ghost bouton formation ([@R70]) and impair synaptic vesicle endocytosis ([@R46]; [@R95]). Based on biochemical studies, actin may also bind and regulate human PMCA to modulate Ca^2+^ homeostasis ([@R20]). In mammals, Synapsins have been shown to tether synaptic vesicles to the actin cytoskeleton, thereby regulating the vesicle reserve pool and activity-dependent, presynaptic plasticity ([@R14]). In *Drosophila,* mutations in *synapsin* attenuate the formation of NMJ ghost boutons following stimulation ([@R91]). While loss of *cindr* leads to an increase in Synapsin, this is unlikely to explain the accompanying ghost bouton formation, because Synapsin overexpression does not cause this phenotype. Although we identify elevations in Synapsin and other presynaptic proteins in *Cd2ap* null mice, it will be important in future work to directly confirm a conserved role for *Cd2ap* in the function of mammalian central synapses. In the rat peripheral nervous system, *Cd2ap* was implicated to participate in signal transduction during axonal outgrowth accompanying collateral sprouting, an important contributor to neuronal plasticity ([@R34]).

*CD2AP/cindr,* 14-3-3ζ, and Synaptic Proteostasis {#S11}
-------------------------------------------------

The UPS plays an important role in normal synaptic function ([@R10]) and is strongly implicated in the altered proteostasis that accompanies neurodegenerative disorders, including AD ([@R100]). Proteasome activity is attenuated following loss of *cindr,* causing a concomitant increase in Synapsin and PMCA. While we document evidence of a more generalized increase in polyubiquitinated proteins, other synaptic proteins (e.g., Synaptotagmin and Syntaxin) did not appear affected, consistent with at least some selectivity. Our observations in *Cd2ap* null mice support a conserved role in UPS regulation and synaptic protein turnover. Prior studies in both *Aplysia* ([@R24]) and rat brain ([@R48]; [@R62]) have implicated the UPS in the regulation of Synapsin levels. We confirmed that both PMCA and Synapsin are likely UPS targets in the *Drosophila* nervous system based on knockdown of a core proteasome subunit. In published work, application of proteasome inhibitors potentiated synaptic transmission at the larval NMJ ([@R83]). Our studies suggest that CD2AP/Cindr regulates the UPS in concert with 14-3-3ζ. Loss of *14-3-3ζ* phenocopies *cindr.* Besides the previously reported attenuation of NMJ synaptic strength ([@R11]), we show that *14-3-3ζ* mutants trigger ghost bouton formation and impair UPS activity, leading to elevations of Synapsin and PMCA. Moreover, Cindr associates and genetically interacts with 14-3-3ζ, consistent with participation in a common regulatory pathway. 14-3-3ζ protein abundance is exquisitely sensitive to changes in the *cindr* gene dosage. Prior investigations indicate that 14-3-3ζ expression in the *Drosophila* nervous system likely depends on stabilization in protein complexes ([@R59]). CD2AP and its closely related mammalian paralog CIN85 have previously been linked to the UPS, particularly in the context of receptor tyrosine kinase signaling ([@R13]; [@R43]; [@R82]; [@R86]). In addition, studies in both *Drosophila* cells and rat hippocampal culture demonstrate that 14-3-3 proteins possess chaperone-like activity and may promote degradation by delivering substrates to the proteasome ([@R71]; [@R80]; [@R99]). Conversely, in myeloma cell culture, 14-3-3ζ antagonized proteasome assembly and activity ([@R30]), suggesting the possibility of a distinct, context-dependent impact on proteostasis. We therefore hypothesize that Cindr/CD2AP may serve as a scaffold to both stabilize 14-3-3ζ and regulate its interactions with key synaptic targets ([Figure 7E](#F7){ref-type="fig"}).

*CD2AP* and AD Susceptibility {#S12}
-----------------------------

GWASs have identified numerous susceptibility loci for AD ([@R47]), but in most cases the responsible genes and relevant mechanisms remain obscure. In a *Drosophila* modifier screen targeting homologs of candidate genes at AD risk loci, we previously reported that *cindr* knockdown enhances Tau-induced neurodegeneration ([@R78]). Our follow-up investigations in *Drosophila* link *cindr* to several interrelated neuronal mechanisms, including endocytosis, Ca^2+^ homeostasis, synaptic neurotransmission and plasticity, and the UPS, that are also strongly implicated in AD pathogenesis ([@R26]). Based on proteomics in a large human brain autopsy cohort, cortical CD2AP protein levels were anti-correlated with multiple Synapsins, and in the setting of AD neuropathology, this relationship was significantly enhanced. This result is consistent with a model in which UPS-dependent synaptic proteostasis is sensitive to CD2AP protein levels and AD pathological changes compromise proteasome activity. In AD postmortem brain tissue, neurofibrillary tangles label strongly for both ubiquitin ([@R69]) and 14-3-3ζ ([@R89]). Moreover, 14-3-3ζ can bind misfolded and hyperphosphorylated Tau and modulate its aggregation ([@R71]; [@R74]). Thus, our finding that *cindr* and *14-3-3ζ* cooperate in synaptic proteostasis in the *Drosophila* nervous system ([Figure 7E](#F7){ref-type="fig"}) highlights an attractive hypothesis for their similar joint contribution to AD susceptibility.

Based on AD GWASs ([@R36]; [@R45]; [@R47]), the association signal at *CD2AP* is localized to several intergenic single-nucleotide polymorphisms, which are in strong linkage disequilibrium and positioned approximately 45 kb proximal to the gene promoter. In ROS-MAP, we previously found that the *CD2AP* risk allele is associated with neurofibrillary tangle pathological burden ([@R15]). Based on the largest available datasets ([@R6]; [@R72]), *CD2AP* risk alleles are associated with moderately increased gene expression across various tissues, including in the brain. This may suggest that reduced *CD2AP* expression is protective for AD; however, this interpretation contradicts our experimental findings that *cindr/CD2AP* (1) is required for neuronal homeostasis and synaptic function and (2) knockdown enhances Tau-induced neurodegeneration. Moreover, the true causal variant or variants at the *CD2AP* locus remain unknown. A sequencing study identified several AD cases harboring a rare, *CD2AP* coding variant (K633R) predicted to be damaging ([@R90]). Although this finding requires replication, it underscores the importance of fine mapping to definitively identify the responsible allelic variants and their mechanisms. Furthermore, because available brain RNA sequencing data are from bulk tissue, we are unable to differentiate the impact of *CD2AP* risk alleles on gene expression in neurons versus other cell types (e.g., astrocytes, endothelial cells, or microglia). *CD2AP* is broadly expressed, and although our studies define important neuronal requirements, prior work highlights complementary functions in other cell types and tissues ([@R5]; [@R17]; [@R31]). Finally, it is possible that susceptibility genes and the implicated biological pathways have dynamic and pleiotropic relationships with AD phenotypes, even flipping from protection to risk during distinct temporal or cell-type-specific disease phases ([@R21]). For example, while reduced neuronal \[Ca^2+^\] may attenuate synaptic strength and thereby increase vulnerability to early AD synaptic dysfunction, the identical perturbation may protect against late excitotoxic mechanisms ([@R67]; [@R84]). Thus, it is possible, if not likely, that *CD2AP* impinges on multiple targets and pathways to affect AD pathogenesis. In conclusion, although substantial challenges remain, functional dissection of susceptibility genes like *CD2AP* holds enormous promise for refinement of AD mechanistic models and development of improved therapeutics.

STAR★METHODS {#S13}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S15}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Joshua M. Shulman (<joshua.shulman@bcm.edu>). All *Drosophila* strains generated for this study are available on request without restriction. No other unique reagents were generated in this study.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S16}
--------------------------------------

### Drosophila {#S17}

Mixed sexes of flies (approximately 50% male and 50% female) were used for all experiments, where possible. Flies were raised on molasses-based food at 25°C with constant darkness unless otherwise noted. The full list of fly strains/genotypes used can be found in the [Key Resources Table](#T1){ref-type="table"}. For clarity, detailed experimental genotypes are noted in Figure legends or with the relevant assay methods, below.

### Mouse {#S18}

All animals were treated in compliance with the US Department of Health and Human Services and Baylor College of Medicine IACUC guidelines. All experiments were performed in male mice of the same age, using animals maintained on a normal 12-hour light-dark cycle.

### Human Subjects {#S19}

The Religious Orders Study and Rush Memory and Aging Project (ROSMAP) participants were free of known dementia at enrollment, agreed to annual clinical evaluations, and signed an informed consent and Anatomic Gift Act donating their brains at death, approved by the Institutional Review Board at Rush University ([@R8]). AD clinical diagnoses were made following National Institute of Neurological and Communicative Disorders and Stroke--Alzheimer's Disease and Related Disorders Association recommendations ([@R58]). AD neuropathologic diagnosis was made based on intermediate or high likelihood of AD by criteria from the [@R63]. Clinical and demographic features of the ROSMAP decedents included in this study can be found in [Table S2](#SD1){ref-type="supplementary-material"}.

METHOD DETAILS {#S20}
--------------

### *Drosophila* stocks and husbandry {#S21}

All experimental genotypes are indicated in relevant figure legends or are specified with the description of the relevant assay methods, below. A complete list of fly strains used can be found in the [Key Resources Table](#T1){ref-type="table"}. The *cindr*^*1*^ null allele was generated by FLP-FRT recombination ([@R73]; [@R18]) between two P-element strains, *PBac{WH}cindr\[f01073\]* and *PBac{RB}CG1554,* that flank the *cindr* locus ([Figure 1A](#F1){ref-type="fig"}). The resulting *cindr*^*1*^ null allele was recombined onto an *FRT82B* chromosome, and this strain was used for all experiments. Studies of *cindr* mutant flies used either *cindr*^*1*^ homozygotes *(cindr*^*1*^ */ cindr*^*1*^) or the transheterozygous genotype, *cindr*^*1*^ */ Df(3R)Exel6217*, denoted in text and Figures as *cindr*^*1*^ or *cindr*^*1/Df*^, respectively. A *yw; FRT82B* isogenic strain was used as the wild-type control strain since *cindr*^*1*^ was recombined into this genetic background. Transgenic rescue strains (*GR1* and *GR2*) were generated via ϕC31-mediated integration of BAC constructs containing the entire *cindr* genomic locus. Transgenic flies were generated (38KBps, CH321--76E05, [bacpac.Chori.org](https://bacpac.Chori.org)). Midi-Prep amplification of CH321--76E05 BAC was carried out overnight and plasmids were isolated and purified using the PureLink™ Hi-pure Plasmid DNA Purification Kit (Thermo Fisher Scientific). The purified *cindr* BAC was injected into VK37 fly embryos, allowing second chromosome specific integration of the *cindr BAC* to the second chromosome. 60 new founder/G0 males were crossed to virgin females and stocks were and balanced on CyO. Two transformants were obtained (Stock 17 and 21). A second BAC transgenic, CH321--90L16 BAC (90KBps), was generated by Genetivision, Inc. All studies using the transgenic *cindr* BAC, examined the genomic rescue contruct in heterozygosity (e.g., *GR1 / +; cindr*^*1*^ */ Df(3R)Exel6217* is abbreviated in Figures as *cindr*^*1/Df*^ *+ GR1*). For survival assays, newly enclosed animals (20 flies per vial) and incubated at 25°C. Surviving animals were counted every 3 days. Each data point is a mean of 3 trials.

### Histology and immunofluorescence {#S22}

For hematoxylin and eosin staining, heads from adult flies were fixed in 8% glutaraldehyde (EM grade) and embedded in paraffin. 5um frontal microtome sections were prepared (Leica) and treated as described in [@R16]. For immunostaining of the NMJ: Larvae were reared at 25°C and dissected at the third wandering instar stage. Larvae were dissected in Hemolymph- Like 3 (HL3) solution (110 mM NaCl, 5 mM KCl, 10 mM NaHCO~3~,10 mM MgCl~2~, 5 mM trehalose, 30 mM sucrose, and 5 mM HEPES, pH 7.2) and fixed in 100% Methanol for 20 minutes. After fixation and washes in PBST (PBS containing 0.3% Triton X-100), larvae were blocked for 1 h in PBST containing 5% normal goat serum, incubated overnight with primary antibody at 4°C, washed, incubated with secondary antibodies for 2 h at room temperature, washed, and mounted in Vectashield (Vector Laboratories) for imaging. All NMJ studies were restricted to muscles 6/7 in abdominal section 2. Immunostaining of adult fly brains used a similar protocol except dissections were performed in 1x PBST and fixation was performed with 4% paraformaldehyde. For immunofluorescence, we used the following antibodies and dilutions (see also [Key Resources Table](#T1){ref-type="table"}): mouse anti-Dlg, 1:150; mouse anti-SNORF1 (Synapsin), 1:25; mouse anti-Bruchpilot (Brp), 1:100; mouse anti-Chaoptin; mouse anti-Repo, 1:500; Rat anti-Elav, 1:100; Guinea Pig anti-EPS15, 1:250; mouse anti-PMCA, 1:200; mouse anti-FK1, 1:100; Mouse anti-FK2, 1:500; rabbit anti-GFP, 1:250; mouse anti-GFP FITC conjugate, 1:100 (used for [Figures 1B](#F1){ref-type="fig"}, [1D](#F1){ref-type="fig"}, and [S1D](#SD1){ref-type="supplementary-material"}--[S1F](#SD1){ref-type="supplementary-material"}); 1:250; DyLight 649 conjugated anti-horseradish peroxidase, 1:150; and CY3-conjugated anti-horseradish peroxidase, 1:100. Secondary antibodies used were all diluted at 1:500, including Alexa Fluor 488 goat anti-mouse, Alexa Fluor 488 goat anti-rabbit, and Alexa Fluor 546 goat anti-rabbit. Larva NMJ images were acquired using Z stack with a 0.67 step at 40x, 1.2 numerical aperture oil-immersion objective using a confocal microscope, while adult fly brain images were acquired using Z stack with a 2.00 step at 20x using a Confocal microscope. Immunostaining expression analysis at the NMJ were quantified by obtaining the average of 6 mean intensity per area of bouton per NMJ per genotype and normalizing to controls. For NMJ studies of Synapsin expression and ghost boutons, the following genotypes were used ([Figures 2C](#F2){ref-type="fig"}--[2F](#F2){ref-type="fig"}): (1, control) *yw;* (2) *cindr*^*1*^ */ Df(3R)Exel6217;* or (3) *GR1 / +; cindr*^*1*^ */ Df(3R)Exel6217.* For characterization of *14-3-3ζ* loss-of-function and interaction with *cindr* genotypes were as follows ([Figure 6C](#F6){ref-type="fig"}): (1) *yw*; (2) *cindr*^*1*^ */ +*; (3) *14-3-3ζ*^*2.3*^ */ +*; (4) *cindr*^*1*^*/ Df(3R)Exel6217*; (5) *14-3-3ζ*^*2.3*^ */ 14-3-3ζ*^*2.3*^; (6) *14-3-3ζ*^*2.3*^ */ +; cindr*^*1*^ */* +. For complementary studies of *14-3-3ζ* overexpression ([Figure 6D](#F6){ref-type="fig"}), the experimental genotypes were as follows: (1) *Elav-Gal4 / Y;* +, (2) *Elav-Gal4 / Y; UAS-14-3-3ζ / +*; (3) *Elav-Gal4 / Y; cindr*^*1*^*/ Df(3R) Exel6217*; (4) *Elav-Gal4 / Y; cindr*^*1*^*/ Df(3R)Exel6217, UAS-14-3-3ζ.* GFP intensity of brain expressing GFP-CL1 were normalized to nc82 staining, and is reported relative to controls; the following genotypes were examined ([Figure 5A](#F5){ref-type="fig"}): (1, control) *Elav-Gal4 / Y; UAS-GFP-CL1/+;* +) and (2, *cindr*^*1/Df*^*) Elav-Gal4 / Y; UAS-GFP-CL1/+; cindr*^*1*^*/ Df(3R)Exel6217.*

### Western Blots {#S23}

For western blots, we used the following additional antibodies and dilutions (see also [Key Resources Table](#T1){ref-type="table"}): anti-SNORF1 (Synapsin), 1:100; mouse anti-Actin, 1:500; rabbit anti-Syt2, 1:1000; rabbit anti-Leonardo (*Drosophila* 14-3-3ζ), 1:1000; rabbit anti-GFP, 1:1000; rat anti-syntaxin, 1:1000, guinea-pig anti-synaptophysin, 1:500; rabbit anti-14-3-3ζ (Human, used for [Figure 7A](#F7){ref-type="fig"}), 1:1000; mouse anti-PMCA, 1:1000; mouse anti-PSD95, 1:500; mouse anti-tubulin clone DM1A, 1:1000; mouse anti- RPT5, 1:300; and mouse anti-FK2, 1:1000.

### TUNEL Assay {#S24}

TUNEL staining was performed using the FragEL DNA Fragmentation Detection Kit from Calbiochem (EMD Millipore Corp., MAUSA). 10-day old adult fly brains were dissected in PBST and then fixed in 4% paraformaldehyde for 20 minutes on ice. Brains were washed with PBST 4 times for 15 minutes/wash and then blocked overnight at 4°C. Brains were then incubated in 100mM Sodium Citrate with 10% triton-x for 30 minutes at 65°C and then washed 3 times with PBST at room temperature. Brains were equilibrated (equilibration buffer) for 15 minutes at room temperature, and then incubated in a 1:9 mixture of Terminal deoxynucleotidyl transferase (Tdt) enzyme and Tdt Labeling Buffer for 2--3 hours at 37°C. Brains were washed 4 times for 15 minutes/wash at room temperature and then mounted on slide with Vectashield (with DAPI). Images were acquired using Z stack with a 2.00 step at 20x using a confocal microscope and apoptotic neurons were counted.

### Immunoprecipitation-Mass Spectrometry (IP-MS) {#S25}

*cindr*^*CA06686*^ fly heads were homogenized in lysis buffer (50 mM Tris pH7.4, 150 mM NaCl, 10% glycerol, 0.5% NP-40) containing complete protease inhibitor (Roche). Homogenized samples were subjected to centrifugation at 20,000 g for 20 min at 4°C. Supernatants were incubated in Chromotek-GFP-Trap Agarose Beads (Allele Biotechnology) in a rotator at 4°C. Cindr complex was eluted from the GFP-agarose beads and samples were subjected to nanoLC-MS/MS analysis with a nano-LC II (Thermo Scientific) coupled to Thermo Velos pro (Thermo Scientific) mass spectrometer as described in detail in [@R101]. For confirmation of Cindr interactions, Cindr:GFP was immunoprecipitated with anti-GFP from head homogenates (*Elav-Gal4; UAS-cindr.GFP / +* and *Elav-Gal4 / Y; UAS-cindr.GFP/* +). Control flies (Ctrl) were *Elav-Gal4/ +* and *Elav-Gal4/Y.* 200 fly heads were grinded with a pestle in lysis buffer. After centrifugation at 15,000 g for 30 minutes to precipitate debris, brain lysate were collected and then incubated in Chromotek-GFP-Trap Agarose Beads (Allele Biotechnology) for 2--3 hours at 4°C. Beads were then centrifuged, washed with lysis buffer 6 times, and then 40ul of Lamelli buffer was added to samples for western blot. In [Figure 1E](#F1){ref-type="fig"}, paired input (3%) and IP samples were run together for each of the two blots shown (Left & Right).

### GCaMP Ca^2+^ Imaging {#S26}

Protocol for Ca^2+^ imaging was modified from [@R98]. Third-instar larval fillets were prepared in ice-cold HL-3.1, which contained 110 mM NaCl, 5 mM KCl, 10 mM NaHCO~3~, 10 mM MgCl~2~, 5 mM trehalose, 30 mM sucrose, and 5 mM HEPES, pH 7.2. A total of 7 mM L-glutamic acid was added to HL-3.1 to desensitize glutamate receptors and prevent muscle contraction during the course of experiment. The VNCs was severed from the dorsal brain lobes to prevent peristalsis. Dissected fillets were allowed to equilibrate to room temperature in HL3.1 containing 1.5 mM Ca^2+^ for at least 15 min before imaging. Type 1b boutons on muscle 6 of abdominal segment A4 were brought to focus with a 25x water-immersion objective on an SP8 Leica Confocal microscope. Using Leica software, fluorescence signal was captured for mCHERRY and for GCaMP6G (Average of 6 type 1B boutons/NMJ). The bath solution was then exchanged to HL3.1 containing 0.5mM CaCl~2~. Two minutes after bath exchange, fluorescence signal was captured at the same settings. Bath solution was then further exchanged to nominally Ca^2+^ free HL3.1. Fluorescence signals were then captured again 2 min and 9 min after bath exchange. NMJ stimulation was carried out using 90mM K^+^ for 10 minutes as described by [@R93]. Recorded electrophysiology traces were analyzed using ImageJ software. Regions not containing an axon terminal and close to a region of interest (ROI) were selected as background. Mean pixel intensity from the background regions was subtracted from that of ROI for each fluorescence channel. Experiments were performed in *cindr*^*1/Df*^ *(Elav-Gal4 / +* or *Y; +; cindr*^*1*^ */ UAS-GCaMP6m-T2A-mCherry, Df(3R)Exel6217)* or *cindr*^*1/Df*^ *+ GR1* controls *(Elav-Gal4 / +* or *Y; cindr*^*1*^ */ UAS-GCaMP6m-T2A-mCherry, Df(3R)Exel6217).*

### Electrophysiology {#S27}

ERG recordings were carried out as previously described ([@R75]). Briefly, adult flies were glued to a glass slide. A recording probe was placed on the surface of the eye, and a reference probe was inserted into the thorax. A fly eye was exposed to a flash of white light for 1 s. Responses were recorded and analyzed with AXON™-pCLAMP8 software. For NMJ electrophysiology, free moving *Drosophila* larvae at the third-instar stage were dissected in HL3.1 buffer without Ca^2+^, and recordings were performed at various extracellular Ca^2+^ concentrations ([@R85]). Ca^2+^ was provided as a chloride salt at the indicated concentrations. Larval motor axons were severed and Excitatory Junction Potentials (EJPs) were recorded from muscle 6 of abdominal segments A2 and A3 at room temperature. EJPs and mEJPs were analyzed using pClamp6 (Molecular Devices) and Mini Analysis Program (Synaptosoft) software, respectively. EJP amplitudes were corrected for nonlinear summation as previously described ([@R56]). For quantification of the resting membrane potential, we calculated the baseline from different recordings from different genotypes at various \[Ca^2+^\] concentrations. There were no differences in input resistance, time constant [t,]{.smallcaps} and resting membrane potential among different genotypes tested in the experiments shown. Total quanta released during 10-Hz stimulation was determined by dividing the amplitude of the EJP by the average mini EJP amplitude. The neurophysiology studies of *cindr*^*1/Df*^ ([Figures 3A](#F3){ref-type="fig"}--[3G](#F3){ref-type="fig"}) use the following experimental genotypes: (1) *cindr*^*1*^ */ Df(3R)Exel6217;* (2 Ctrl) *yw;* or (3) *GR1 / +; cindr*^*1*^ */ Df(3R)Exel6217.* For the characterization of *14-3-3ζ*^*2.3*^ and interactions with *cindr* ([Figures 6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}), the following genotypes were used: (1) *yw*; (2) *cindr*^*1*^ */ +*; (3) *14-3-3ζ*^*2.3*^ */ +*; (4) *cindr*^*1*^*/ Df(3R)Exel6217*; (5) *14-3-3ζ*^*2.3*^ */ 14-3-3ζ*^*2.3*^; (6) *14-3-3ζ*^*2.3*^ */ +; cindr*^*1*^ */* +.

### Proteasome Activity Assay {#S28}

*In vitro* proteasome activity assays were carried out using the 20S proteasome activity Assay Kit protocol. 15 fillet preparations of 3^rd^ instar larval were performed to remove fat bodies, lysed in lysis buffer and then centrifuged for 30 minutes at 15,000 rpm. The supernatant was obtained and concentration of protein per microliter was quantified using the Pierce BCA protein kit. Sample Lysates of equal protein amount were added to an assay mixture of proteasome substrate (Suc-LLVY-AMC), assay buffer and water (adding up to 100ul) and then incubated for 2 hours at 37°C in a 96 well plate. Fluorescence intensity was read using a 380/460 nm filter set in a fluorometer.

### Transmission Electron Microscopy (TEM) {#S29}

TEM of *Drosophila* adult retinae and larval neuromuscular junctions were performed as in prior work ([@R88]). *Drosophila* larval neuromuscular junctions (abdominal segment 3, muscle 6/7) were imaged following standard Electron Microscopy procedures using a Ted Pella Bio Wave processing microwave with vacuum attachments. Briefly, whole 3rd instar larvae were dissected at room temperature in modified Karnovski's fixative in 0.1 M Sodium Cacodylate buffer at pH 7.2 and subsequently fixed overnight to three days in the same fixative. The pre-fixed fillets were then irradiated in the fixed again, followed by 3 millipore water rinses, post-fixed with 1% aqueous Osmium Tetroxide, and rinsed again 3 times with millipore water. Concentrations from 30%--100% of Ethanol were used for the initial dehydration series, followed with Propylene Oxide as the final dehydrant. Samples were gradually infiltrated with 3 ratios of propylene oxide and Embed 812, finally going into 3 changes of pure resin under vacuum. Samples were allowed to infiltrate in pure resin overnight on a rotator. The samples were embedded into flat silicone molds and cured in the oven at 62°C for at least three days. The polymerized samples were thin-sectioned at 48--50 nm and stained with 1% uranyl acetate for ten minutes followed by 2.5% lead citrate for two minutes the day before TEM examination. For *Drosophila* retina ultrastructure was imaged using a Ted Pella Bio Wave processing microwave with vacuum attachments. Briefly, whole heads were dissected in accordance to preserve the brain tissue. The tissue was covered in 2% paraformaldehyde, 2.5% Glutaraldehyde, in 0.1 M Sodium Cacodylate buffer at pH 7.2. After dissection the heads were incubated overnight up to three days in the fixative on a rotator. The pre-fixed heads were then fixed again, followed by 3x millipore water rinses, post-fixed with 1% aqueous osmium tetroxide, and rinsed again 3x with millipore water. Concentrations from 25%--100% of Ethanol were used for the initial dehydration series, followed with Propylene Oxide as the final dehydrant. Samples were gradually infiltrated with 3 ratios of propylene oxide and Embed 812, finally going into 3 changes of pure resin under vacuum. Samples were allowed to infiltrate in pure resin overnight on a rotator. The samples were embedded into flat silicone molds and cured in the oven at 62°C for three days. The polymerized samples were thin-sectioned at 48--50 nm and stained with 1% uranyl acetate for ten minutes followed by 2.5% lead citrate for two minutes before TEM examination. Grids for both Retina and NMJ were viewed in a JEOL JEM 1010 transmission electron microscope at 80kV. Images were captured using an AMTXR-16 mid-mount 16 mega-pixel digital camera in Sigma mode. ImageJ was used to adjust contrast.

### Human brain proteomics {#S30}

Selective reaction monitoring-mass spectrometry proteomics was performed using frozen tissue from dorsolateral prefrontal cortex (DLPFC), as detailed in prior publications ([@R102]). Briefly, \~20 mg of brain tissue from each subject was homogenized in denaturation buffer (8M urea, 50 mM Tris-HCl pH 7.5,10 mM DTT, 1 mM EDTA), and 400 ug aliquots were subjected to iodoacetamide alkylation and trypsin digestion, followed by solid phase extraction. At least 2 proteotypic peptides ^13^C/^15^N-labeled on carboxyterminal lysine and arginine were selected to measure each target protein (New England Peptide, Gardner, MA). Following standard quality metrics, quantification was based on the peptide with the highest signal to noise ratio: CD2AP (VLFEYIPQNEDELELK), SYN1 (LGTEEFPLIDQTFYPNHK), SYN2 (SFRPDFVLIR), and SYN3 (SFKPDFILVR). Experiments were performed on a nano ACQUITY UPLC coupled to TSQ Vantage MS instrument, and data were analyzed using Skyline software (Skyline Software Systems, Inc., Herndon, VA) ([@R55]). Peptide relative abundances were log~2~-transformed and centered at the median.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S31}
---------------------------------------

*Drosophila* and mouse experimental data were analyzed using Prism, version 6.00 (Graph Pad Software, La Jolla, CA, USA). Statistical analyses relied on Student's t tests or Analysis of Variance (ANOVA), followed by Dunnett's post hoc test for multiple comparisons. The significance threshold was set at p \< 0.05, and is noted in figures using the following convention: \*, p \< 0.05; \*\*, p \< 0.01; \*\*\*, p \< 0.001. Otherwise, results are noted at "not significant" (ns). Error bars in all analyses represent the standard error of the mean (SEM). Sample sizes for all analyses are indicated in Figure legends, referring to the number of animals examined or replicate studies performed. Analyses of human proteomics data were performed using SAS version 9.4 (SAS Institute Inc, Cary, NC), and statistical significance was determined at a level of 0.05. Spearman correlations examined bivariate relationships between CD2AP and SYN1--3. Linear regression models examined the association of CD2AP with synaptic proteins after the adjustment for age, sex and postmortem intervals. In these models, the expression level of individual synaptic protein was the continuous outcome, and CD2AP expression was the predictor. The corresponding regression coefficient estimates the difference in synaptic protein level with every log2 unit increase in CD2AP. We repeated the analyses by further adjusting for pathologic diagnosis of AD. Next, we augmented the models by adding an interaction term between pathologic AD diagnosis and CD2AP. A significant interaction term would suggest the CD2AP associations with synaptic proteins differ by AD diagnosis. Stratified linear regression analyses were also performed by AD diagnosis.

DATA AND CODE AVAILABILITY {#S32}
--------------------------

Selective reaction monitoring-mass spectrometry proteomics and associated clinicopathologic data for ROSMAP human postmortem samples is available for request from the RADC Research Resource Sharing Hub (<http://www.radc.rush.edu/>) and the AMP-AD Knowledge Portal on Synapse (<https://doi.org/10.7303/syn2580853>).
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![Cindr Is Present at Synapses and Associates with Other Synaptic Proteins\
(A) *cindr* genomic locus is shown, including coding exons (dark gray), untranslated regions (light gray), and transposon insertion alleles (triangles) used in this study. *cindr*^*CA06686*^ (green) contains a GFP coding exon, flanked by splice acceptor and donor sequences and resulting in an N-terminal tagged-Cindr protein (Cindr^GFP^). Recombination was performed between 2 FRT-containing *piggy*Bac insertions (orange) flanking the *cindr* locus. In the null allele *cindr*^*1*^, the gene coding sequence is replaced with a hybrid transposable element containing a *mini-white* gene. A chromosomal deficiency, *Df(3R)Exel6217,* is shown (*Df*, red), along with two bacterial artificial chromosomes (BACs) (blue), used for transgenic genomic rescue constructs (*GR1* and *GR2*). See also [Figure S2A](#SD1){ref-type="supplementary-material"} for Cindr protein structure.\
(B--D) Cindr expression and subcellular localization were assayed using Cindr^GFP^, enhanced by staining with anti-GFP. See also [Figure S1](#SD1){ref-type="supplementary-material"}.\
(B) In the adult brain, Cindr^GFP^ (green) is predominantly within the neuropil and colocalizes with the presynaptic active zone marker Bruchpilot (nc82) (red). Scale bar, 100 μm.\
(C) In the larval peripheral nervous system, Cindr^GFP^ (green) reveals a punctate distribution in the body wall muscles and is enriched within the synaptic terminal boutons at neuromuscular junctions, where it predominantly colocalizes with the presynaptic marker horseradish peroxidase (anti- HRP) (blue), but not the postsynaptic membrane marker discs large (anti-DLG) (red). Scale bar, 10 μm.\
(D) Cindr^GFP^ (green) shows partially overlapping localization (arrowheads) with candidate binding partners at the neuromuscular junction, including Synapsin (anti-Syn) (red) and Synaptotagmin (anti-Syt) (blue). Scale bar, 10 μm.\
(E) Candidate Cindr binding partners were confirmed using pull-down assays from head homogenates. Cindr coimmunoprecipitates with actin, Synaptotagmin (Syt), 14-3-3ζ, Synapsin (Syn), plasma membrane calcium ATPase (PMCA), and regulatory proteasome subunit 5 (Rpt5), but not Syntaxin (Syx).](nihms-1537447-f0002){#F1}

![*cindr* Is Dispensable for Development and Maintenance of the Adult Brain but Is Required for Synapse Maturation at the NMJ\
(A) *cindr*^*1/Df*^ flies (*cindr*^*1*^*/Df(3R)Exel6217*) show reduced survival that is rescued by either heterozygous *GR1* or *GR2* transgenic BAC constructs.\
(B) Top: H&E staining of frontal brain sections from 30-day-old *cindr*^*1/Df*^ or controls (*cindr*^*1/Df*^ *+ GR1*) demonstrate no overt neuronal loss or other apparent pathology. Scale bar, 50 μm. See also [Figure S2C](#SD1){ref-type="supplementary-material"}. Bottom: transmission electron micrographs of tangential retinal sections reveal normal architecture in 30-day-old animals, including photoreceptor clusters and surrounding pigment cells, comprising the ommatidia. Scale bar, 5 μm. See also [Figure S4](#SD1){ref-type="supplementary-material"}.\
(C) Levels of Synapsin protein (anti-Syn) (green) at the larval neuromuscular junction are increased in *cindr*^*1/Df*^ animals versus control (*yw*). Scale bar, 10 μm.\
(D) *cindr* loss of function causes an increased number of ghost boutons (arrows). Incompletely differentiated terminals are identified by the presence of the presynaptic marker horseradish peroxidase (anti-HRP) (green) but absence of surrounding postsynaptic membranes, colabeled with discs large (anti-DLG) (red). Scale bar, 10 μm. See also [Figure S3B](#SD1){ref-type="supplementary-material"}.\
(E and F) Quantification (n \> 10) of Synapsin immunofluorescence (E) and ghost boutons (F), as shown in (C) and (D), respectively. All error bars denote SEM. \*\*\*p \< 0.001; ns, not significant. See also [Figure S5](#SD1){ref-type="supplementary-material"}.\
(G-I) Electron micrographs of larval neuromuscular junctions. Control synaptic terminals (G) are surrounded by a sub-synaptic reticulum (SSR) associated with the postsynaptic membrane (dotted line). Normal appearance of the active zone (asterisk), synaptic vesicles (SV), and mitochondrion (m) is also indicated. In *cindr* mutants, synaptic defects include (H) synaptic terminals lacking a sub-synaptic reticulum and (I) boutons with decreased synaptic vesicle density. *cindr* mutant synaptic terminals are also characterized by increased numbers of enlarged vesicles (arrowheads in G and I). Scale bar, 600 nm. See also [Figure S6](#SD1){ref-type="supplementary-material"}.](nihms-1537447-f0003){#F2}

![*cindr* Disrupts Neurotransmission and Synaptic Plasticity\
(A) Based on neurophysiology studies at the larval neuromuscular junction, *cindr*^*1/Df*^ causes a reduction in excitatory junction potentials (EJPs).\
(B) EJP amplitude was quantified at different \[Ca^2+^\] and corrected for nonlinear summation.\
(C) *cindr*^*1/Df*^ enhances paired-pulse facilitation.\
(D) Quantification (n \> 6) of paired-pulse facilitation.\
(E) *cindr*^*1/Df*^ accelerates synaptic depression during rapid stimulation (10 Hz) and attenuates recovery during a subsequent period of 0.2-Hz stimulation. Representative traces (1200 s) are shown.\
(F) Quantification of the rapid stimulation and recovery. Data were corrected for nonlinear summation and normalized to initial EJP amplitude. Two-way ANOVA was performed with Sidak's test, highlighting significant differences (p \< 0.05) between genotypes after 150 s during 10-Hz stimulation and after 180 s during 0.2-Hz recovery.\
(G) Total estimated synaptic vesicle release during the 10-Hz stimulation experiment. Control or *cindr*^*1/Df*^ (n = 16) terminals released 220,000 ± 12,305 (mean ± SEM) versus 153,986 ± 16,469 vesicles, respectively.\
(H) Cooperativity plots reveal that *cindr* mutants require higher \[Ca^2+^\] to achieve the same EJP response, but the preserved slope (1.2) suggests intact calcium-vesicle release coupling. All error bars denote SEM. \*\*p \< 0.01; \*\*\*p \< 0.001; ns, not significant. See also [Figures S2](#SD1){ref-type="supplementary-material"} and [S7](#SD1){ref-type="supplementary-material"}.](nihms-1537447-f0004){#F3}

![*cindr* Disrupts Calcium Homeostasis at the Synapse\
(A and B) Calcium (Ca^2+)^ concentrations at the larval neuromuscular junction were assessed using the GCaMP sensor (green) compared with an mCHERRY internal standard (red). *cindr* mutants show reduced presynaptic Ca^2+^ under either resting or stimulated conditions. Increasing extracellular pH to 8.8 restores presynaptic Ca^2+^.\
(A) Representative GCaMP imaging from experiments at rest. Scale bar, 10 μm.\
(B) Quantification of GCaMP experiments (n \> 9 for all genotypes and conditions).\
(C) Levels of PMCA protein (anti-PMCA) (green) at the larval neuromuscular junction are increased in *cindr*^*1/Df*^ mutants. Scale bar, 10 μm.\
(D) Quantification (n = 6) of PMCA immunofluorescence.\
(E) Increasing extracellular pH to 8.8 suppresses the *cindr*^*1/Df*^ paired-pulse facilitation phenotype.\
(F) Quantification (n = 6) of paired-pulse experiment. All error bars denote SEM. \*\*p \< 0.01; \*\*\*p \< 0.001; ns, not significant. See also [Figures S2](#SD1){ref-type="supplementary-material"} and [S7](#SD1){ref-type="supplementary-material"}.](nihms-1537447-f0005){#F4}

![*cindr* Regulates Ubiquitin-Protea- some System Activity and Protein Turnover\
(A) Synapsin (Syn) and PMCA protein levels are increased in *cindr*^*1/Df*^ adult heads. Other presynaptic proteins, including Synaptotagmin (Syt) and Syntaxin (Syx), were unchanged.\
(B) Quantification of western blot results in (A) from at least 3 replicate experiments.\
(C) In 5-day-old adults, the GFP-CL1 proteasome reporter is barely detectable (anti-GFP) (green) in brains from controls but is strongly increased in *cindr*^*1/Df*^, indicating impaired ubiquitin-proteasome activity. Scale bar, 100 μm.\
(D) Quantification (n \> 6) of GFP-CL1 intensity.\
(E) Decreased proteasome activity is confirmed in both *cindr*^*1/Df*^ trans-heterozygous and *cindr*^*1*^ homozygous animals, as well as *14-3-3ζ*^*2.3*^ homozygotes, using an *in vitro* assay that liberates a fluorescent peptide (Suc-LLVY-AMC) following cleavage. 3rd-instar larval homogenates were normalized for total protein levels and quantified (n \> 6).\
(F) *cindr* loss of function triggers an increase in polyubiquitinated proteins (FK2 antibody) in brains from 5-day-old adults. All error bars denote SEM. \*\*p \< 0.01; \*\*\*p \< 0.0001; ns, not significant. See also [Figure S8](#SD1){ref-type="supplementary-material"}.](nihms-1537447-f0006){#F5}

![*cindr* Functions with *14-3-3ζ* to Affect Synapse Structure and Function\
(A--D) *14-3-3ζ* loss of function phenocopies *cindr* at the larval neuromuscular junction, causing impaired synaptic transmission (A and B) and increased ghost bouton numbers (C). *cindr* and *14-3-3Z* also show evidence of dominant genetic interactions (A--D), consistent with their coordinate function in a common pathway. Double-heterozygous allelic combinations of *cindr*^*1*^ with *14-3-3ζ*^*2.3*^ show EJP reductions (A and B) and increased NMJ ghost boutons (C) similar to *cindr*^*1/Df*^ or *14-3-3ζ*^*2.*3^ homozygotes.\
(A and B) Representative traces (A) and quantification (B) (n \> 8) of evoked excitatory junction potentials (EJPs).\
(C) Quantification (n \> 6) of ghost bouton numbers.\
(D) Overexpression of *14-3-3ζ* reciprocally causes a reduction in ghost bouton numbers and *cindr* is epistatic. At least 6 animals were evaluated per genotype (*Elav-Gal4/Y* is present in all groups).\
(E) *cindr* mutants cause a decrease in 14-3-3ζ protein levels in the adult brain of 5-day-old animals.\
(F) Quantification (n \> 5) of 14-3-3ζ protein expression.\
(G) *cindr* shows a haploinsufficient requirement for 14-3-3ζ protein expression in brains of 5-day-old animals, and *cindr/14-3-3ζ* double heterozygotes show further reduction.\
(H) Quantification (n \> 4) of 14-3-3ζ protein expression. All error bars denote SEM. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001; ns, not significant. See also [Figure S10](#SD1){ref-type="supplementary-material"}.](nihms-1537447-f0007){#F6}

![CD2AP Has a Conserved Role in Synaptic Proteostasis in Mammals\
(A) Whole-brain homogenates from 5-month-old *Cd2ap*^*−/*−^ null mice show increased levels of Synapsin (SYN), Synaptophysin (SYP), and PMCA, but not Synaptotagmin (SYT), compared with wild-type control littermates. 14-3-3ζ protein expression is reduced.\
(B) Quantification of the western blot result (n \> 3). All error bars denote SEM. \*\*p \< 0.01; \*\*\*p \< 0.001; ns, not significant.\
(C) *In vitro* proteasome assay reveals reduced ubiquitin-proteasome system activity in *Cd2ap*^*−/*−^ whole-brain homogenates normalized for total protein levels and quantified (n \> 3).\
(D) Cortical levels of CD2AP and Synapsin-1 proteins are significantly anti-correlated (ρ = −0.478, p \< 0.0001), based on selective reaction monitoring-mass spectrometry proteomics from 838 human brain autopsies. The linear regression model relating CD2AP and Synapsin-1 was robust to adjustment for AD pathology, age of death, sex, and postmortem interval. See also [Tables S2](#SD1){ref-type="supplementary-material"}--^[S4](#SD1){ref-type="supplementary-material"}^ and [Figure S11](#SD1){ref-type="supplementary-material"}.\
(E) Hypothetical model for proposed nervous system function of Cindr/CD2AP. CD2AP functions in concert with 14-3-3ζ to target selected synaptic proteins for UPS-mediated degradation, promoting calcium homeostasis, synaptic neurotransmission, and plasticity.](nihms-1537447-f0008){#F7}

  ----------------------------------------------------------------- ------------------------------------- ------------------------------------------
  REAGENT or RESOURCE                                               SOURCE                                IDENTIFIER
  Antibodies                                                                                              
  mouse anti-SNORF1 (Synapsin)                                      DSHB                                  RRID: AB_2313867
  rat anti-Elav                                                     DSHB                                  RRID: AB_528218
  mouse anti-Dlg                                                    DSHB                                  RRID: AB_528203
  mouse anti-Bruchpilot                                             DSHB                                  RRID: AB_2314866
  mouse anti-Chaoptin                                               DSHB                                  RRID: AB_528161
  mouse anti-Repo                                                   DSHB                                  RRID: AB_528448
  guinea pig anti-EPS15                                             [@R44]                                N/A
  rabbit anti-GFP                                                   Thermo Fisher                         A-11122
  mouse anti-GFP (B-2) FITC-conjugated                              Santa Cruz                            SC-9996
  rabbit anti-Leonardo (*Drosophila* 14--3--3ζ)                     [@R11]                                N/A
  rat anti-Syntaxin                                                 [@R35]                                N/A
  guinea pig anti-Synaptophysin                                     Synaptic Systems                      Cat\#101 004
  mouse anti-Actin Clone C4                                         Sigma Aldrich                         MAB1501
  mouse anti-PMCA (5F10)                                            Abcam                                 AB2825
  mouse anti-26S Proteasome p50 (112)-RPT5                          Santa Cruz                            RRID: SC_65745
  mouse anti-FK1                                                    Enzo                                  BML-PW8805--0500
  mouse anti-FK2                                                    Enzo                                  BML-PW8810--0100
  mouse anti-Tubulin Clone DM1A                                     Sigma Aldrich                         T6199
  rabbit anti-Syt2                                                  [@R50]                                N/A
  rabbit anti-14--3--3ζ (Human)                                     Abcam                                 RRID: AB_51129
  Alexa 488-conjugated secondary antibodies                         Jackson ImmunoResearch Labs           RRID: AB_2338059
  Alexa Cy3-conjugated secondary antibodies                         Jackson ImmunoResearch Labs           RRID: AB_2338013
  DyLight 649 Anti-Horseradish Peroxidase                           Jackson ImmunoResearch Labs           N/A
  Cy3 AffiniPure Goat Anti-Horseradish Peroxidase                   Jackson ImmunoResearch Labs           Lot\#137589
  Critical Commercial Assays                                                                              
  20S Proteasome Activity Assay Kit                                 Millipore                             Cat\#APT280
  FragEL DNA Fragmentation Detection Kit Fluorescent - TdT Enzyme   Millipore                             Cat\#QIA39
  Deposited Data                                                                                          
  Proteomic Data (CD2AP & Synapsin1--3)                             This study                            <https://doi.org/10.7303/syn2580853>
  Experimental Models: Organisms/Strains                                                                  
  *w^1118^; 14--3--3ζ^12BL^/CyO*                                    Bloomington Drosophila Stock Center   BDSC_9572; Flybase ID: FBal0065577
  *w^1118^; 14--3--3ζ^2.3^/CyO*                                     Bloomington Drosophila Stock Center   BDSC_9573; Flybase ID: FBal0059634
  *M{UAS-14--3--3ζ.ORF}ZH-86Fb*                                     FlyORF                                FlyORF_F001492; Flybase ID: FBst0500670
  *Syn^97^*                                                         [@R28]                                Flybase ID: FBal0155774
  *UAS-Synapsin-GFP*                                                [@R91]                                N/A
  *CH321--90L16-VK37* (*GR2*)                                       Genetivision, Inc.                    N/A
  *P{PTT-GA}cindr^CA06686^* (*cindr^GFP^*)                          Bloomington Drosophila Stock Center   BDSC_50802; Flybase ID: FBal0211634
  *UAS-Tau^R406W^*                                                  [@R97]                                N/A
  *Rpt6-RNAi: P{KK108783}VIE-260B*                                  Vienna Drosophila RNAi Center         VDRC_v100620; Flybase ID: FBal0235814
  *UAS-cindr-PC-GFP*                                                [@R37]                                N/A
  *UAS-CL1-GFP*                                                     [@R68]                                N/A
  *PBac{WH}cindr\[f01073\]*                                         Exelixis at Harvard Medical School    Exelixis_f01073; Flybase ID: FBti0049715
  *PBac{RB}CG1554*                                                  Exelixis at Harvard Medical School    Exelixis_e03116; Flybase ID: FBst1014789
  *yw;; FRT82B cindr^1^/TM6B*                                       This study                            N/A
  *CH321--75E06-VK37* (*GR1*)                                       This study                            N/A
  *UAS-GCaMP6m-P2A-mCHERRY*                                         [@R88]                                N/A
  *w^1118^, Df(3R)Exel6217, P{XP-U} Exel6217/TM6B, Tb^1^*           Bloomington Drosophila Stock Center   BDSC_7695; Flybase ID: FBst0007695
  *Cd2ap^KO^* mouse                                                 [@R77]                                N/A
  Recombinant DNA                                                                                         
  P\[acman\] BAC CH321--76E05 (*chr3R:30806623..30844282*)          [@R92]                                N/A
  P\[acman\] BAC CH321--90L16 (*chr3R:30787614..30871086*)          [@R92]                                N/A
  ----------------------------------------------------------------- ------------------------------------- ------------------------------------------

###### Highlights

-   *cindr,* fly homolog of the Alzheimer's risk gene *CD2AP,* encodes a synaptic protein

-   *cindr* mutants disrupt synaptic vesicle recycling and release and impair plasticity

-   Cindr and 14-3-3ζ regulate the proteasome and presynaptic calcium homeostasis

-   *Cd2ap* mouse and human brain studies support a conserved role in synapse proteostasis
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